SCHEMBL7786069

SCHEMBL7786069

CC(=O)c1cc(C)cc(Br)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPMT P51580 1/20 0.46
CA5A P35218 1/20 0.46
KDR P35968 1/20 0.41
CYP2A6 P11509 1/20 0.41
HCAR1 Q9BXC0 1/20 0.40
RAB9A P51151 5/20 0.39
HTT P42858 1/20 0.39
LMNA P02545 1/20 0.39
NPC1 O15118 3/20 0.39
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPK1 P28482 2/20 0.38
STAT3 P40763 1/20 0.38
STAT1 P42224 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
FFAR4 Q5NUL3 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29547990 1.00 TPMT (0.46) TPMTCA5AKDRCYP2A6HCAR1
SCHEMBL343284 0.87 CA5A (0.52) CA5ARAB9ALMNANPC1MAPT
SCHEMBL15709749 0.87 CA5A (0.52) CA5ARAB9ALMNANPC1MAPT
SCHEMBL95695 0.85 TPMT (0.62) TPMTCA5ACYP2A6HCAR1RAB9A
SCHEMBL2624954 0.85 TPMT (0.55) TPMTCA5ACYP2A6HCAR1RAB9A
SCHEMBL696914 0.84 TPMT (0.70) TPMTCA5AKDRHCAR1LMNA
SCHEMBL30762678 0.84 TPMT (0.70) TPMTCA5AKDRHCAR1LMNA
SCHEMBL19723419 0.84 HTT (0.46) TPMTKDRHCAR1RAB9AHTT
SCHEMBL15700662 0.82 TPMT (0.43) TPMTKDRHCAR1RAB9AHTT
SCHEMBL1363884 0.82 PARP1 (0.50) TPMTKDRHCAR1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236610-A1 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF BEIGENE, LTD. (KY) 2025-07-24 US disclosed
US-20250059175-A1 Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2025-02-20 US disclosed
US-12195449-B2 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof BEIGENE, LTD. (KY) 2025-01-14 US disclosed
US-20240317714-A1 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF BEIGENE, LTD. (KY) 2024-09-26 US disclosed
US-20230373963-A1 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF BEIGENE, LTD. (KY) 2023-11-23 US disclosed
US-11616204-B2 Organic electroluminescence device and organometallic compound for organic electroluminescence device SAMSUNG DISPLAY CO., LTD. (KR) 2023-03-28 US disclosed
CN-113024608-A Organic electroluminescent device and organometallic compound for organic electroluminescent device 三星显示有限公司 2021-06-25 CN disclosed
US-20210175442-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND ORGANOMETALLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2021-06-10 US disclosed
WO-2018106646-A1 AMINOTRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2018-06-14 WO disclosed
WO-2018106646-A1 AMINOTRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2018-06-14 WO disclosed
US-20170001960-A1 BIPYRIDYL COMPOUND JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2017-01-05 US disclosed
CN-104788442-A Preparation method of substituted benzoxazole derivative Hunan huateng pharmaceutical co ltd 2015-07-22 CN disclosed
US-9085606-B2 Beta amino acid derivatives as integrin antagonists SAINT LOUIS UNIVERSITY (US) 2015-07-21 US disclosed
US-20150038534-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2015-02-05 US disclosed
US-8901156-B2 Compounds and methods TEMPERO PHARMACEUTICALS, INC. (US) 2014-12-02 US disclosed
US-20140038910-A1 Beta Amino Acid Derivatives as Integrin Antagonists SAINT LOUIS UNIVERSITY (US) 2014-02-06 US disclosed
US-20130059883-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2013-03-07 US disclosed
EP-0735142-B1 Process for producing (R)-styrene oxides SUMIKA FINE CHEMICALS CO LTD (JP) 2001-10-24 EP disclosed
US-5717116-A TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) 1998-02-10 US disclosed
EP-0735142-A2 Process for producing (R)-styrene oxides SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) 1996-10-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317714-A1 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF HIPK1, HIPK3, HIPK2 TPMT 2001/4885CA5A 3206/4885KDR 3069/4885
US-20140038910-A1 Beta Amino Acid Derivatives as Integrin Antagonists ITGB2, ITGAL, ITGB1 TPMT 2756/4885CA5A 3387/4885KDR 29/4885
US-20170001960-A1 BIPYRIDYL COMPOUND CBR1, NR0B2, ERBB2 TPMT 4573/4885CA5A 3138/4885KDR 188/4885
US-20230373963-A1 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF HIPK1, HIPK3, HIPK2 TPMT 2001/4885CA5A 3206/4885KDR 3069/4885
US-20250059175-A1 Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals PIK3CA, PIK3CD, PIK3R5 TPMT 3081/4885CA5A 2898/4885KDR 517/4885
US-20150038534-A1 COMPOUNDS AND METHODS XDH, LPXN, CCNY TPMT 3208/4885CA5A 1141/4885KDR 3680/4885
US-20130059883-A1 COMPOUNDS AND METHODS XDH, LPXN, CCNY TPMT 3208/4885CA5A 1141/4885KDR 3680/4885
US-12195449-B2 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof HIPK1, HIPK3, HIPK2 TPMT 2001/4885CA5A 3206/4885KDR 3069/4885
US-20250236610-A1 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF HIPK1, HIPK3, HIPK2 TPMT 1962/4885CA5A 3143/4885KDR 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.